Genomics can advance the potential for probiotic cultures to improve liver and overall health

Current Pharmaceutical Design

Volumn 14, Issue 14, 2008, Pages 1376-1381

  O'Sullivan, Daniel J ^a  

^a CARGILL INC   (United States)

Author keywords

Bifidobacterium; Genomics; Lactobacillus; Liver health; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; ASCORBIC ACID; BACTERIAL DNA; BACTERIOCIN; BIOLOGICAL PRODUCT; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; LACTOBACILLUS RHAMNOSUS EXTRACT; LACTULOSE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOLIC FATTY LIVER; ANTIMICROBIAL ACTIVITY; BACTERIAL GENOME; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BACTERIUM CULTURE; BIFIDOBACTERIUM; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFICACY; ENDOTOXEMIA; FUNCTIONAL GENOMICS; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; LIVER DISEASE; LIVER FUNCTION; MICROBIAL GROWTH; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

BIFIDOBACTERIUM; GENOME, BACTERIAL; HUMANS; IMMUNE SYSTEM; INTESTINES; LACTOBACILLUS; LIVER DISEASES; PROBIOTICS;

EID: 47249132132     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784480234     Document Type: Review

References (57)

1. Henle J. Pathologishe Untersuchingen, in G Rosen (Ed), Henle: An Miasmata and Contagia. Baltimore, The Johns Hopkins Press 1840.
2. Koch R. Die Aetiologie der Milzbrand-Krankheit, begründet auf die Entwicklungsgeschichte des Bacillus Anthracis. Beitrage zur Biologie der Pflanzen 1876; 2: 277-310.
3. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-78.
4. Metchnikoff E. The Prolongation of Life. New York, GP Putman's & Sons 1908.
5. Metchnikoff O. Life of Elie Metchnikoff. New York, Houghton Mifflin Company 1921.
6. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, et al. Probiotics: From myth to reality. Demonstration of functionality in Animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 1999; 76: 279-92.
7. Kumar SGV, Singh SK, Goyal P, Dilbaghi N, Mishra DN. Beneficial effects of probiotics and prebiotics on human health. Pharmazie 2005; 60: 163-71.
8. O'Sullivan DJ. Screening of intestinal microflora for rffective probiotic bacteria. J Ag Food Chem 2001; 49: 1751-60.
9. Sanders ME. Probiotics. Food Technol 1999; 53: 67-77.
10. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discov Today 2003; 8: 692-700
11. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: Lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-7.
12. Clark JM, Brancati FL, Diehl AM. Nonalcoholoc fatty liver disease. Gastroenterol 2002; 122: 1649-57.
13. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association Hepatol 2002; 35: 367-72.
14. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Amer J Gastroenterol 2003; 98: 960-67.
15. Nardone G, Rocco A. Probiotics - A potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol 2004; 38(6 Suppl S): S121-2.
16. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979; 23: 403-11.
17. Solga SF. Probiotics can treat hepatic encephalopathy. Med Hypoth 2003; 61: 307-13.
18. Nair S, Cope K, Terence RH, Diehl AM. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 1200-4.
19. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatol 2005; 41: 422-33.
20. Adachi Y, Moore LE, Bradford BU, Gao WS, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterol 1995; 108: 218-24.
21. Shuliat'ev IS, Il'chenko LIu, Vinnitskaia EV, Petrakov AV, Sil'verstrova SIu. Lactulose in treatment of hepatic encephalopathy in patient with liver cirrhosis. Eksperimental'Naia i Klinicheskaia Gastroenterologiia, 2002; 5:38-41.
22. Solga SF, Diehl AM. Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatol 2004; 39: 1197-200.
23. Petuely F, Kristen G. Changing the intestinal flora of infants. Ann Paediat 1949; 172: 183-4.
24. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Clin Consequences Drugs 1997; 53: 930-42.
25. Muting D, Eschrich W, Mayer JP. The effect of bacterium bifidum on intestinal bacterial flora and toxic protein metabolites in chronic liver disease. Am J Proctol 1968; 19: 336-432.
26. Jia L, Zhang MH. Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats. World J Gastroenterol 2005; 11: 908-11.
27. Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.
28. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004; 5: 64-7.
29. Liu Q, Duan ZP, Ha da K, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatol 2004; 39: 1441-49.
30. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-7.
31. Li.Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatol 2003; 37: 343-50.
32. Ma DL, Forsythe P, Bienenstock J. Live Lactobacillus reuterl is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004; 72: 5308-14.
33. Viljanen M, Kuitunen M, Haahtela T, Juntunen-Backman K, Korpela R, Savilahti E. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Ped Aller Immunol 2005; 16: 65-71.
34. Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, Falk W, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 2003; 70: 165-73.
35. Wells CL, Maddaus MA, Reynolds CM, Jechorek RP, Simmons RL. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 1987; 55: 2689-94.
36. Adawi D, Ahrne S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol 2001; 70(3): 213-220.
37. Zhu FG, Marshall JS. CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells. J Leukocyte Biol 2001; 69: 253-62.
38. Berg RD. Probiotics, prebiotics or 'conbiotics'. Trends Microbiol 1998; 6: 89-92.
39. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999; 65: 351-4.
40. Haddadin MSY, Awaisheh SS, Robinson RK. The production of yogurt with probiotic bacteria isolated from infants in Jordan. Pakistan J Nutr 2004; 3: 290-3.
41. Meile L, Ludwig W, Rueger U, Gut C, Kaufmann P, Dasen G, et al. Bifidobacterium lactis sp. nov, a moderately oxygen tolerant species isolated from fermented milk. Sys App Microbiol 1997; 20: 57-64.
42. Cai YM, Matsumoto M, Benno Y. Bifidobacterium lactis Meile et al 1997 is a subjective synonym of Bifidobacterium animalis (Mitsuoka 1969, Scardovi and Trovatelli 1974). Microbiol Immunol 2000; 44: 815-20.
43. Ventura M, Zink R. Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl Environ Microbiol 2002; 68: 6429-34.
44. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, et al. In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. Amer J Clin Nutr 200l; 73(2Suppl):386S-92.
45. Archibald F. Lactobacillus plantarum, an organism not requiring iron. FEMS Microbiol Letts 1983; 19: 29-32.
46. Posey JE, Gherardini FC. Lack of a role for iron in the Lyme disease pathogen. Science 2000; 288: 1651-53.
47. O'Sullivan DJ, O'Gara F. Traits of fluorescent Pseudomonas spp-involved in the suppression of plant root pathogens. Microbiol Rev 1992; 56: 662-76.
48. Bezkorovainy A. 1989. Iron transport and utilization by bifidobacteria, in Bezkorovainy A, Miller-Catchpole R (eds): Biochemistry and physiology of bifidobacteria. CRC Press, pp 147-76.
49. Mevissen-Verhage EA, Marcelis JH, Harmsen-Van Amerongen WC, de Vos NM, Verhoef J. Effect of iron on neonatal gut flora during the first three months of life. Eur J Clin Microbiol 1985; 4: 273-8.
50. Schell MA, Karmirantzou K Snel B, Vilanova D, Berger B, Pessi G, et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci USA 2002; 99: 14422-7
51. Pridmore RD, Berger B, Desiere F, Vilanova D, Barretto C, Pittet AC, et al. The genome sequence of the probiotic intestinal bacterium Lactobacillus johnsonii NCC 533. Proc Natl Acad Sci USA 2004; 101: 2512-7.
52. Altermann E, Russell WM, Azcarate-Peril MA, Barrangou R, Buck BL, McAuliffe O, et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 2005; 102(11): 3906-12.
53. Azcarate-Peril MA, McAuliffe O, Altermann E, Lick S, Russell WM, Klaenhammer TR. Microarmy analysis of a two-component regulatory system involved in acid resistance and proteolytic activity in Lactobacillus acidophilus. Appl Environ Microbiol 2005 71(10): 5794-804.
54. Shields DC, Sharp PM. Synonymous codon usage in Bacillus subtilis reflects both translational selection and mutational biases. Nucleic Acids Res 1987; 15: 8023-40.
55. Callanan M. Mining the probiotic genome: Advanced strategies, enhanced benefits, perceived obstacles. Curr Pharm Des 2005; 11(1): 25-36.
56. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 2005; 11(8): 1047-53.
57. Simonson OE, Svahn MG, Tomquist E, Lundin KE, Smith CI. Bioplex technology: Novel synthetic gene delivery pharmaceutical based an peptides anchored to nucleic acids. Curr Pharm Des 2005; 11(28): 3671-80.